Scientific publications
Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab
M. González Cao, S. Viteri, C. Garrán, Y. Nieto, J. Aristu, M. Ponz and S. Martín Algarra
Oncology Department, Clínica Universitaria de Navarra, Pamplona, Spain
Magazine: Clinical and Translational Oncology
Date: Feb 1, 2007
Radiation Oncology Medical OncologyWe report here a taxol–bevacizumab-responsive metastatic melanoma case.
Although the patient had been heavily pretreated for two years, she did not show any stabilisation or objective response of her disease. After treatment with taxol and bevacizumab combination an impressive response was obtained.
CITATION Clin Transl Oncol. 2007 Feb;9(2):119-20
you maybe interested
WHAT TECHNOLOGY
DO WE USE?
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
OUR
PROFESSIONALS
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
WHY CHOOSE
THE CLINICA?
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.
